Moving forward with new data and approaches: A fresh look at anthracyclines in non-Hodgkin's lymphoma

Dino Amadori

Research output: Contribution to journalArticle

Abstract

Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalHematology Reports
Volume3
Issue number3 SUPPL.
DOIs
Publication statusPublished - 2011

Fingerprint

Anthracyclines
Non-Hodgkin's Lymphoma
Doxorubicin
Dexrazoxane
Vincristine
Standard of Care
Chelating Agents
Prednisone
Liposomes
Cyclophosphamide
Appointments and Schedules
Drug Therapy
Cardiotoxicity
Therapeutics

Keywords

  • Anthracycline
  • Doxorubicin
  • Liposomal doxorubicin
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Moving forward with new data and approaches : A fresh look at anthracyclines in non-Hodgkin's lymphoma. / Amadori, Dino.

In: Hematology Reports, Vol. 3, No. 3 SUPPL., 2011, p. 1-3.

Research output: Contribution to journalArticle

@article{2b795426e3884274990e2e803abb3dd6,
title = "Moving forward with new data and approaches: A fresh look at anthracyclines in non-Hodgkin's lymphoma",
abstract = "Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.",
keywords = "Anthracycline, Doxorubicin, Liposomal doxorubicin, Non-Hodgkin's lymphoma",
author = "Dino Amadori",
year = "2011",
doi = "10.4081/hr.2011.s3.e1",
language = "English",
volume = "3",
pages = "1--3",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PagePress",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Moving forward with new data and approaches

T2 - A fresh look at anthracyclines in non-Hodgkin's lymphoma

AU - Amadori, Dino

PY - 2011

Y1 - 2011

N2 - Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.

AB - Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.

KW - Anthracycline

KW - Doxorubicin

KW - Liposomal doxorubicin

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=82755182374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755182374&partnerID=8YFLogxK

U2 - 10.4081/hr.2011.s3.e1

DO - 10.4081/hr.2011.s3.e1

M3 - Article

C2 - 22586509

AN - SCOPUS:82755182374

VL - 3

SP - 1

EP - 3

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 3 SUPPL.

ER -